Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From WuXi AppTec

What’s In Store For CROs, CDMOs – “Stay In Your Swim Lane”, Consolidation, Divestitures

Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.

Commercial Financing

China CEO Interview: Gracell Aims To Enter US CAR-T Sector Through Partnerships, Faster Delivery

With the success of the partnership between J&J and partner Legend, more Chinese cell therapy developers are now looking to enter the US market. But for a complex product like a CAR-T therapy, the journey to the West is not short of challenges. Nasdaq-listed Gracell Bio wants to give it a shot based on quicker delivery and cost-effectiveness advantages.

China Business Strategies

China Further Tightens Oversight Of Human Genetic Research

Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.

China Gene Therapy

'Still Bad Out There' - Drug Makers In APAC Prepare For Worst Before It Gets Better

Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.

China Commercial
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Laboratory Testing Services
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Technologies
      • ADMET
      • Bioinformatics
  • Other Names / Subsidiaries
    • Crelux GmbH
    • Faxian Therapeutics
    • JW Biotechnology (Shanghai) Co., Ltd
    • OXGENE
    • ResearchPoint Global
    • STA Pharmaceutical Co., Ltd.
    • WuXi PharmaTech
    • WuXi Merger Limited
    • XenoBiotic Laboratories, Inc.
UsernamePublicRestriction

Register